pharmaphorum

JANUARY 8, 2021

According to one analysis, conducted by Global Data, approximately 67% of trial disruptions during the early stages of the pandemic were due to the suspension of enrolment, followed by the delayed start of planned trials at 18.4% How can pharma improve the patient-centricity of its trials during COVID-19 and beyond?

104

104

pharmaphorum

OCTOBER 27, 2022

Ipsen’s Dr Oleksandr Gorbenko and MediPaCe’s Dr Sandeep Bagga examine the ‘impact’ of engaging with patients and how patients view their experiences of discussing impact measurement with life science companies. The concept of patient centricity has been a key talking point across the healthcare ecosystem for years.

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies 104

pharmaphorum

NOVEMBER 23, 2022

But when viewed in isolation, these robust data sets may only provide HTA bodies with a blinkered view of the broader impact of an intervention. Traditionally, HTA submissions leverage significant amounts of data: data about cost, clinical efficacy, benefits, and risks.

52

52

ALiEM - Pharm Pearls

APRIL 12, 2024

Figure 3: Chest CT angiogram showing the pigtail catheter (arrow) in the left mainstem bronchus Figure 4: Bronchoscopy view of the left mainstem bronchus showing the pigtail catheter This case highlights one of the more rare and potentially severe complications of small-bore chest tubes. This was confirmed on bronchoscopy (Figure 4).

Inpatient 180

Inpatient 180

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

A comparative analysis of the efficacy and safety of therapeutic interventions in phlegmasia cerulea dolens. His symptoms began earlier in the day and progressed over just a few hours. He had no known thromboembolic risk factors. He had no known thromboembolic risk factors. The preferred imaging modality is doppler ultrasound. Ann Vasc Dis.

Medical Schools 150

Medical Schools Diabetes 150

Pharmaceutical Technology

NOVEMBER 22, 2022

All this, and the latest pharma industry news , comment, data, and analysis from GlobalData. Click here to view the latest issue of Pharmaceutical Technology Focus. Most recently, after a tumultuous 45 days, Liz Truss resigned as the UK’s prime minister paving the way for Rishi Sunak to take on the mantle.

93

93

Big Molecule Watch

JANUARY 29, 2024

On January 10, 2024, the USPTO published guidelines for assessing enablement in view of Amgen v. The post USPTO Publishes Enablement Guidelines in view of Amgen v. Sanofi and other recent court cases (“the Guidelines”). Sanofi appeared first on Big Molecule Watch.

57

57

PharmaState Academy

MARCH 3, 2024

To address these challenges, you propose a comprehensive analysis combining historical sales data, market insights, and customer behavior patterns. Identifying top-performing regions and areas for improvement empowers sales teams to refine their strategies and drive growth. The conversation is heated, with voices rising as opinions clash.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

APRIL 30, 2021

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how they can find a smoother path to market. Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. Time for a NICE change.

Communication 98

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

European Pharmaceutical Review

OCTOBER 13, 2023

Analysis of microbial growth in cultures using fluorescent optical respirometry Study results FOR significantly shortened the time of the studies from three days for bacteria and five days for yeasts to 10 hours and 15 hours, respectively, the authors noted.

98

98

pharmaphorum

OCTOBER 20, 2022

Historically, competitive and market analysis data has been stored in spreadsheets. Executing an effective commercial success strategy requires extensive planning and implementation within pharmaceutical companies that spans teams, functions, and geographies.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Data Entry Documentation 98

pharmaphorum

OCTOBER 26, 2020

A new analysis looks at these barriers and asks how they could be overcome. Understanding payer views of preventive care. Preventive care programmes are key to better health outcomes, but several factors are limiting their uptake.

Vaccines 128

Vaccines 128

pharmaphorum

DECEMBER 7, 2022

Source: CT assessments [Haute Autorité de Santé website]; ANSM [Agence Nationale de Sécurité du Médicament et des Produits de Santé]; CRA analysis). Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. Rare diseases: a flawed system.

Drug Pricing 104

Drug Pricing Drug Development 104

ALiEM - Pharm Pearls

DECEMBER 22, 2023

In a 7-year retrospective analysis at a regional trauma center, 57.4% In a 7-year retrospective analysis at a regional trauma center, 57.4% An 84-year-old female presented with a chief complaint of right hip pain after a fall 12 hours prior to presentation. She denied loss of consciousness. Abdomen : BS+, nondistended, nontender.

158

158

ALiEM - Pharm Pearls

MARCH 22, 2024

A 53-year-old woman with no significant past medical history presented to the emergency department with a 3-day history of double vision on leftward gaze. She endorsed mild, intermittent headaches associated with diplopia when looking to the left. Physical Exam Vitals : Temp 36.7°C; She is alert and oriented.

166

166

pharmaphorum

AUGUST 4, 2020

A new analysis from consulting firm CRA has honed in on the different challenges faced in four European markets – England, France, Germany and Scotland – and looked at how manufacturers can increase the chances of a successful appraisal. Source: CRA Analysis. Rates of approval.

Labelling 120

Labelling 120

pharmaphorum

JANUARY 24, 2022

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. IBM said it “remains committed to Watson, our broader AI business, and to the clients and partners we support in healthcare IT.”

Cerner 109

Cerner 109

pharmaphorum

DECEMBER 17, 2021

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Digital health: making medicine more human. Driving transformation and innovation in healthcare.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharmacy Joe

MAY 5, 2024

Further information on what fluids to avoid in these patients is provided by a 2012 analysis of the Saline versus Albumin Fluid Evaluation study. Members of my Hospital Pharmacy Academy have access to a video-based training on Practical Strategies for Acutely Elevated ICP from a pharmacist’s point of view.

Hospitals 52

Hospitals Inpatient 52

pharmaphorum

AUGUST 19, 2021

The Good Clinical Trials Collaborative (GCTC) has published a draft guidance document, and is asking for the life sciences sector to make its views known. A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter what they do or where they are based.

Documentation 104

Documentation Communication 104

Pharmacy Joe

FEBRUARY 25, 2024

Members of my Hospital Pharmacy Academy have access to practical training on the treatment of anaphylaxis from a pharmacist’s point of view. The mechanism of action for glucocorticoids is to form a complex with receptors on cell membranes, translocate this complex to the nucleus, and inhibit the production of new inflammatory mediators.

Hospitals 75

Hospitals Inpatient 75

Express Pharma

APRIL 2, 2024

An analysis by McKinsey has projected that on account of broader adoption of these technologies, the EBIDTA earnings of the Indian pharma industry will go up by 45-75 per cent in the next 10 years. However, the industry also faces several challenges like increasing competition, regulatory hurdles, pricing pressures and rising R&D costs.

Drug Development 59

Drug Development Clinic Management Communication 59

European Pharmaceutical Review

MARCH 12, 2024

Traditionally, the optimisation of pharmaceutical processes is often based on empirical analysis. An alternative approach is the application of modern computational simulation tools” Traditionally, the optimisation of pharmaceutical processes is often based on empirical analysis.

Dosage 84

Dosage 84

Pulses

JUNE 13, 2023

An analytical tool that some have used to help is called a “gap analysis.” Gap analysis is a process of comparing your current state to your desired future state. Many individuals or organizations use this tool for internal analysis to see where they are currently, evaluate where they want to go, and develop a plan to bridge the gap.

52

52

pharmaphorum

JULY 7, 2022

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Fuld & Company Blog

DECEMBER 21, 2023

Outcome The target list developed by Fuld allowed the firm to gain an encyclopedic view of the potential targets in this niche industry. Subsequently, the focus shifted to identifying complementary add-on opportunities, aiming to enhance the initial investment’s value and facilitate strategic expansion.

52

52

pharmaphorum

SEPTEMBER 27, 2021

An analysis of FDA data into trials of cancer drugs approved since 2015 found that 24 out of 31 cancer drug trials had fewer than 5% black trial participants – and this is despite black women being disproportionately affected. This already significant industry is growing – it is estimated to be worth $1.27 trillion by end of 2020.

Vaccines 120

Vaccines Communication Drug Development 120

pharmaphorum

OCTOBER 28, 2021

Three views on technology improving clinical trial efficiency. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Time for a new model in patient access.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

NOVEMBER 11, 2020

Other promising benefits include administrative automation and population health risk analysis. AI based diagnostic image analysis is showing a lot of promise. Abid Rahman from Intouch Group tells pharmaphorum how AI-based technology is solving challenges across healthcare systems, pharmaceutical companies, and patient treatment.

Pharmaceutical Companies 139

Pharmaceutical Companies Pharmaceutical Companies Communication Hospitals 139

pharmaphorum

FEBRUARY 11, 2022

It’s our representation of tracking the deidentified, which is important from a privacy and compliance point of view,” Sun says. “It Though 7,000 rare diseases exist that affect 400 million people globally, a lack of understanding of these diseases can cause a delay in diagnosis and, in turn, treatment. The benefits of accessibility.

104

104

pharmaphorum

JUNE 2, 2021

As more cases were reported and various health stakeholders around the world recommended or discouraged use of the vaccine, HCPs used social media as a platform to make their views known. The formation of blood clots is a necessary process in order for the body to repair damage caused by injury and to slow down bleeding.

Vaccines 104

Vaccines Hospitals 104

pharmaphorum

APRIL 21, 2022

Although beneficial in many ways, this activity-driven approach by its very nature creates a limited view of KOLs which is based primarily on their past activity. Although beneficial in many ways, this activity-driven approach by its very nature creates a limited view of KOLs which is based primarily on their past activity.

52

52

Pharmacy Joe

AUGUST 20, 2023

In an effort to add to the level of evidence for the population of patients with ICH and SBP above 220 mmHg, a group of authors published in JAMA Neurology a post hoc analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage-II trial. However, the study was a post-hoc analysis, not a pre-specified one.

Hospitals 52

Hospitals Inpatient 52

Pharmacy Joe

AUGUST 20, 2023

In an effort to add to the level of evidence for the population of patients with ICH and SBP above 220 mmHg, a group of authors published in JAMA Neurology a post hoc analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage-II trial. However, the study was a post-hoc analysis, not a pre-specified one.

Hospitals 52

Hospitals Inpatient 52

pharmaphorum

NOVEMBER 2, 2020

This is a content standard that ensures clinical data is submitted in a consistent manner, helping to reduce review time and facilitating cross-study analysis. Another content standard, the Analysis Data Model (ADaM), aims to perform a similar function for analysis datasets. ADaM – standardizing analysis datasets.

98

98

pharmaphorum

MARCH 11, 2021

View the webinar* by clicking on the link in the window above or by clicking here. View the webinar* by clicking on the link in the window above or by clicking here. An important source of RWE has, until recently, been locked in the electronic health record (EHR). Deep RWE in practice – early results from the BigCOVIData study.

108

108

pharmaphorum

MAY 6, 2022

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Closing the digital expectation gap in pharma. Combination pricing: access to the future of oncology treatment.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52